Prostate tumor overexpressed-1 (PTOV1), a modulator of the Mediator transcriptional regulatory complex, is expressed at high levels in prostate cancer and other neoplasias in association with a more aggressive disease. Here we show that PTOV1 interacts directly with receptor of activated protein C kinase 1 (RACK1), a regulator of protein kinase C and Jun signaling and also a component of the 40S ribosome. Consistent with this interaction, PTOV1 was associated with ribosomes and its overexpression promoted global protein synthesis in prostate cancer cells and COS-7 fibroblasts in a mTORC1-dependent manner. Transfection of ectopic PTOV1 enhanced the expression of c-Jun protein without affecting the levels of c-Jun or RACK1 mRNA. Conversely, knockdown of PTOV1 caused significant declines in global protein synthesis and c-Jun protein levels. High levels of PTOV1 stimulated the motility and invasiveness of prostate cancer cells, which required c-Jun, whereas knockdown of PTOV1 strongly inhibited the tumorigenic and metastatic potentials of PC-3 prostate cancer cells. In human prostate cancer samples, the expression of high levels of PTOV1 in primary and metastatic tumors was significantly associated with increased nuclear localization of active c-Jun. These results unveil new functions of PTOV1 in the regulation of protein translation and in the progression of prostate cancer to an invasive and metastatic disease.
INTRODUCTION
Prostate tumor overexpressed-1 (PTOV1), identified in our laboratory as a novel gene and protein, is strongly expressed in prostate carcinoma and in high-grade prostatic intraepithelial neoplasia lesions but it is expressed at low levels in benign prostate epithelium. 1, 2 High levels of expression of PTOV1 in prostate tumors and other neoplasias are significantly associated with their proliferative status and with high grade. 2, 3 The protein consists of a tandemly repeated domain joined by a short linker peptide. 1 A PTOV domain was found also in PTOV2 or MED25, a subunit of the Mediator transcriptional regulator, 1, 4, 5 whose structure, in complex with the transcriptional activator VP16, was recently resolved by nuclear magnetic resonance. 6, 7 Although the levels of PTOV1 in cultured prostate cells regulate their proliferative status, 2, 8 and several interactors have been reported, [8] [9] [10] the molecular mechanisms by which PTOV1 might influence the initiation, maintenance and progression of neoplasia have not been sufficiently explored.
Here, we describe the interaction of PTOV1 with the receptor of activated protein C kinase 1 (RACK1), a tryptophan/aspartic (WD) repeat-containing protein highly conserved in eukaryotes.
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RACK1 associates with protein kinase C (PKC) isoforms and additional signaling proteins, suggesting that it might act as a scaffold to recruit elements involved in the regulation of angiogenesis, tumor growth, neuronal response and apoptosis. 12 Broad roles for RACK1 have been documented in a diverse array of cellular processes, including cell spreading through the regulation of focal adhesion kinase and paxillin phosphorylation, 13 regulation of insulin receptor and Insulin growth factor (IGF)-1R signaling through the activation of extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK), 14 or STAT3 activation, 15 cell proliferation 14 or PKC-mediated Ser129 phosphorylation of JNK induced by phorbol esters, tumor necrosis factor-a and UV radiation. 16 More recently, RACK1 was shown to be a core component of the eukaryotic 40S ribosomal subunit, 17 suggesting that it may function as a molecular link connecting cell signaling with the protein translation machinery.
RESULTS

PTOV1 interacts with RACK1
To study novel pathways in which PTOV1 is involved, a yeast twohybrid screening was performed to search for novel interaction partners. The full-length PTOV1 cDNA was used as a bait to screen against approximately 3.5 Â 10 6 clones of a human prostate cancer cDNA library. One clone was identified as RACK1 (Supplementary Figure 1) . The interaction of PTOV1 and RACK1 was confirmed in prostate cancer cells by co-immunoprecipitation of endogenous RACK1 and PTOV1 (Figure 1a ). Pull-down experiments showed that recombinant GST-RACK1 specifically interacted with endogenous PTOV1 (Figure 1b) . Conversely, endogenous RACK1 interacted with the GST-PTOV1 protein and with the PTOV-B domain, but not with the PTOV-A domain (Figure 1c ), suggesting that, although highly related in sequence, the two PTOV1 domains are not functionally equivalent. In addition, endogenous PTOV1 and RACK1 colocalized in the cytoplasm and at membrane ruffles in the majority of cells after stimulation with either IGF-1 or phorbol esther (Figure 1d ).
PTOV1 associates with ribosomes and regulates protein synthesis RACK1, initially described in association with protein kinase C, was subsequently found to be an integral component of the 40S ribosomes. 17, 18 Consistent with its interaction with RACK1, most of endogenous PTOV1 co-sedimented in exponentially growing PC-3 cells with gradient fractions containing the 40S subunits, RACK1 and rpS6 (fraction 3 in Figure 2a ). PTOV1 was also detected in the hydrosol fractions, consistent with our previous description of its cytoplasmic localization. 2 In contrast, PTOV1 was not detected in polysomes. The fraction containing the 40S subunits was correctly identified by the presence eIF4E, as expected from its direct binding to RACK1. 19 Tubulin, described as associated with monosomes and short polysomes, correctly co-sedimented with those fractions. 20 The accurate localization of eIF4E, RACK1, rpS6 and tubulin indicates little or no diffusion of proteins between the gradient fractions. When the cellular levels of RACK1 were lowered by expression of specific short hairpin RNAs (shRNAs), a remarkable decrease in polysome formation was observed, as indicated by the presence of RACK1 and rpS6 only in fractions 3 and 4 containing monosomes 40S, 60S and 80S (Figure 2a) , suggesting a significant inhibition of protein translation, as previously described. [21] [22] [23] [24] As expected, upon RACK1 knockdown, the association of eIF4E with the 40S subunit was also strongly compromised, supporting the conclusion that lower levels of RACK1 result in the formation of stalled initiation complexes and a defect in the initiation step of translation. [21] [22] [23] Under these conditions, PTOV1 failed to cosediment with the 40S ribosomal subunit and a decrease in its expression was also evident (Figure 2a, right panel) . These results indicate that limiting levels of RACK1 prevent the co-sedimentation of PTOV1 with ribosomes. As a further corroboration of its interaction with ribosomes, PTOV1 co-immunoprecipitated with rpS6 ( Figure 2b ) and the two proteins colocalized at discrete cytoplasmic sites in a significant proportion of cells after treatment with IGF-1, reminiscent of the previously observed colocalization of PTOV1 and RACK1 at membrane ruffles (Figure 2c ). Chelation of divalent cations with EDTA, which detaches polysomes from the mRNA component, disrupted the formation of polysomes and caused a significant shift of RACK1 and rpS6 from polysomes to the fractions containing the isolated ribosomal subunits. Under these conditions, the association of PTOV1 with ribosomes did not vary significantly (Supplementary Figure 2) .
Ectopic expression of Green flourescent protein (GFP)-PTOV1 in COS-7 cells stimulated bulk protein synthesis, suggesting that the association of PTOV1 with RACK1 and ribosomes influences protein translation (Figure 2d ). Reciprocally, specific knockdown of endogenous PTOV1 with shRNA ( Supplementary Figure 3a) , or small interfering RNA duplexes (Supplementary Figure 3b) , caused a significant decline in bulk protein synthesis (Figure 2e ). Classic cap-dependent protein translation is regulated by mTORC1, which, when active, hyperphosphorylates 4E-BP1, leading to the release of the cap-binding factor eIF4E and activation of translation. 25, 26 The mTORC1 inhibitor rapamycin only partially inhibited global translation and the enhancement of protein translation promoted by PTOV1 (Figure 2d ), consistent with its previously reported partial inhibition of mTORC1. 24, 27 However, co-transfection with a non-phosphorylatable 4E-BP1 mutant (4EBPm) inhibited basal and PTOV1-enhanced translation, in PTOV1 regulates translation and tumor progression N Marqué s et al agreement with its reported inhibitory effect on cap-dependent translation. 28 These results suggest that the stimulation of protein translation by PTOV1 is dependent on mTORC1.
PTOV1 enhances the translation of c-Jun RACK1 had been previously shown to regulate JNK signaling and c-Jun expression. 16 We thus explored the potential involvement of PTOV1 in this regulation. Transfection of PC-3 cells with increasing amounts of pCMV-HA-PTOV1 was accompanied with about fourfold increase in the levels of c-Jun protein ( Figure 3a ) and a minor increase in RACK1 protein (Figure 3a ) or RACK1 and c-Jun transcript levels (Supplementary Figure 4a) , suggesting a posttranscriptional regulation of c-Jun by PTOV1. The turnover of the c-Jun protein was not significantly affected by ectopic expression of PTOV1, suggesting an action of PTOV1 on protein synthesis (Supplementary Figure 4b) . To analyze the effect of PTOV1 on the rate of c-Jun translation, COS-7 cells transfected with GFP-PTOV1 and Jun-HA were pulse-labeled with [ 35 S]-methionine and Jun-HA was immunoprecipitated, electrophoresed and visualized by fluorography (Figure 3b ). The levels of newly synthesized Jun-HA in cells transfected with GFP-PTOV1 were nearly ninefold greater than in control cells, suggesting that high levels of PTOV1 stimulate the rate of translation of c-Jun. Similar to the effects of PTOV1 on bulk protein synthesis, the upregulation of c-Jun protein induced by transfection of GFP-PTOV1 was inhibited by 4EBPm but Additional experiments indicate that PTOV1 regulates other tiers of c-Jun signaling. Thus, knockdown of PTOV1 caused a significant decline in the levels of phosphorylated c-Jun and the proportion of cells in which the protein was translocated to the nucleus in response to IGF-1, a known activator of c-Jun that promotes its nuclear translocation 30 ( Figures 4a and b) . Furthermore, knockdown of PTOV1 in PC-3 cells strongly compromised the transcriptional activity of the c-Jun-responsive collagen promoter or a construct bearing AP1 response elements (Figure 4c ), suggesting that sufficient levels of PTOV1 are required for a full transcriptional activity of c-Jun. These observations PTOV1 regulates translation and tumor progression N Marqué s et al suggest that PTOV1 is required not only for the translation of c-Jun but also for its activation in response to growth factors.
PTOV1 promotes c-Jun-dependent enhanced motility and invasion, and is required for tumorigenesis and metastasis of PC-3 prostate cancer cells Our prior studies showed that higher levels of PTOV1 are associated with more advanced stages of several types of cancer. 3 Given this association and the above observed regulation of c-Jun expression and activation, known to promote invasion, [31] [32] [33] we studied whether high levels of PTOV1 affected the motility and invasive potential of prostate cancer cells. PC-3 cells transfected with GFP-PTOV1 showed a significantly increased motility in wound-healing assays, as did cells transfected with Jun-HA, compared with control cells (Figure 5a and Supplementary Figure 6 ). Likewise, cells overexpressing PTOV1 or Jun-HA were significantly more invasive than control cells in Transwell-Matrigel assays (Figure 5b and Supplementary Figure 7) . Conversely, specific knockdown of PTOV1 or c-Jun markedly inhibited the invasion of PC-3 cells (Figure 5c ). Cells transfected with GFP-PTOV1 and Tam67, a truncated form of c-Jun that blocks its transcription factor activity, 34 significantly inhibited the motility and invasion induced by GFP-PTOV1 or Jun-HA, 35, 36 indicating that the PTOV1-promoted cell invasion requires c-Jun. Furthermore, transfection of GFP-PTOV1 or Jun-HA in PC-3 cells caused a significant upregulation of SNAI1 protein and transcript (Figures 5d and e) , a well-characterized effector of epithelial-mesenchymal transition, 37, 38 and the mesenchymal markers vimentin and N-cadherin, effects abrogated by co-transfection with Tam67 ( Figure 5d and Supplementary Figure 8) . Similarly, PTOV1 induced increased levels of SNAI1 through the upregulation of c-Jun in MDCK cells (Supplementary Figure 8) . In addition, increased protein levels of the urokinase-receptor and secretion of urokinase and MMP-2 were also observed by transfection of GFP-PTOV1 (Supplementary Figure 9) . 35, 36 However, no significant modulation of E-cadherin, fibronectin or b-catenin, known targets of SNAI1, 39 were observed in PC-3 cells (Figure 5d ) or in MDCK cells (Supplementary Figure 8) , suggesting that PTOV1 and c-Jun induce a partial epithelialmesenchymal transition. 40 To study whether the upregulation of SNAI1 induced by high levels of PTOV1 is mediated by direct transcriptional activation of SNAI1 by c-Jun, as shown for other cell types, 41 chromatin immunoprecipitation experiments were performed. The occupancy of the SNAI1 promoter by PTOV1 and c-Jun was tested with specific antibodies in cells stably overexpressing PTOV1 or Jun-HA. These experiments revealed specific occupancy of the SNAI1 promoter by c-Jun, but not by PTOV1 (Figure 5f ).
Collectively, these observations suggest that high levels of PTOV1 result in increased levels of active c-Jun that, in turn, promote the transcription of SNAI1, ultimately engaging a mesenchymal-like gene program and enhanced cell invasion.
To determine the relevance of PTOV1 in tumorigenesis and prostate cancer progression, PC-3 cells were stably knocked down for PTOV1 by shRNA and inoculated subcutaneously in SCID-beige mice. As illustrated in Figure 6 , knockdown of PTOV1 significantly inhibited tumor growth compared with control cells (Figure 6a ). These differences were clearly reflected in the post-excision T/C weight ratio, which was 16% for tumors grown from shPTOV1 cells, significantly lower (P ¼ 0.0095) than control PC-3 cells. PC-3/ shPTOV1 cells disseminated to distant sites (axillary lymph nodes and lungs) with a significant delay as compared with control cells (Figure 6b ). Figure 6c shows that tumors developed from shPTOV1 cells had a marked reduction in PTOV1 protein levels as well as a strong decrease in the levels of total and active c-Jun, as compared with control tumors. These results provide evidence that PTOV1 is required for the full tumorigenic and metastatic capacities of PC-3 cancer cells in vivo.
Concordant expression of high levels of PTOV1 and active c-Jun in association with prostate cancer progression To evaluate the potential relevance of the above findings in prostate cancer progression, we analyzed the expression of PTOV1 and phosphorylated c-Jun in 20 primary prostate adenocarcinomas without affected lymph nodes or metastasis (non-metastatic prostate adenocarcinomas), 16 primary tumors with lymph node involvement (metastatic primary) and the corresponding matched lymph node metastases (Met). As previously described, 2 epithelial cells from the benign peripheral zone associated with primary non-metastatic tumors showed undetectable or faint staining for PTOV1, whereas tumor cells displayed a strong and significant staining (P ¼ 0.00025; Figure 7 ). This strong expression of PTOV1 was maintained at local and distant metastases ( Figure 7 and Supplementary Figure 10) . Thus, in increasing intensity, the expression levels of PTOV1 followed the order: benign peripheral zone onon-metastatic prostate adenocarcinomasometastatic primarypMet. Phosphorylated c-Jun also showed an increased expression in high-grade Gleason tumors relative to benign peripheral zone, although this difference did not reach statistical significance (Figure 7b ). In lymph node metastases, staining for Taken together, the above evidences link the expression of high levels of PTOV1 in prostate cancer to activation of protein translation and c-Jun signaling, leading to an enhanced growth and invasion in vitro, and tumorigenesis and metastatic spread in vivo. These observations provide a mechanistic explanation of the association of higher levels of PTOV1 with malignant progression in prostate cancer.
DISCUSSION
We had previously found that the expression of abnormally high levels of PTOV1 is significantly associated with tumor progression in prostate cancer and other neoplasias. [1] [2] [3] The evidence presented here unveil a new function for this protein as a regulator of protein translation and c-Jun expression. We have also found that high levels of PTOV1 promote the invasion of prostate Antibodies to acetyl-histone H3 and non-specific IgG of the same species were used as controls. Statistically significant differences were: *Po0.05; **Po0.005; ***Po0.0001. In this study, we show that PTOV1 interacts with RACK1, a regulator of cell signaling, cell migration and ribosomal functions. 17, 42, 43 The functional relevance of this interaction is provided by our gain-of-function and loss-of-function experiments in PC-3 prostate cancer cells and COS-7 fibroblasts, which suggest that PTOV1 acts as a positive regulator of protein translation. More specifically, we have found that PTOV1 requires RACK1 to associate with 40S ribosomes but it is not found in polysomes, suggesting that it may regulate translation initiation. Increased levels of PTOV1 caused a significant stimulation of bulk protein synthesis, including c-Jun synthesis. Of interest, the tandemly repeated PTOV domains share a structural similarity with SPOC domains, 6, 7, 44 present in MINT/SHARP and RBM15, proteins that contain RNA-binding motifs (RRM) and are required for efficient mRNA nuclear export. 45 Although PTOV1 does not contain obvious RRM motifs, our prior observations that PTOV1 shuttles from the cytoplasm to the nucleus, 8 together with the evidence presented here of its ability to regulate the rate of protein translation and to bind isolated ribosomes but not polysomes might suggest its implication in ribonucleoprotein shuttling and regulation of translation initiation.
Our results also suggest that the stimulation of protein translation by high levels of PTOV1 requires mTORC1. Advanced prostate and breast tumors display increased rates of protein translation resulting from higher levels of phospho-4E-BP1 and/ or increased expression of eIF4E, a substrate of mTORC1, in association with cancer progression and reduced survival. 46, 47 This has been linked to an increased activation of the mTOR pathway through different mechanisms. 24, 27, 48 We have found that the stimulation of translation of c-Jun by high levels of PTOV1, which in turn activates the transcription of SNAI1 and enhances invasiveness, is inhibited by a non-phosphorylatable form of 4EB-P1 and by the strong mTORC1 inhibitor PP242. Thus, our results indicate that PTOV1, through its interaction with RACK1 and ribosomes, participates in the translation of mRNAs 
The role of AP1 transcription complexes in promoting cancer cell invasion and metastasis is well established. 49, 50 Post-transcriptional mechanisms also account for the upregulation of c-Jun induced by different stimuli. 51 For instance, loss of cell-to-cell contacts and induction of the invasive phenotype upregulate c-Jun protein levels, without a parallel increase in its mRNA levels. 52 Similarly, we have found that the upregulation of c-Jun protein induced by overexpression of PTOV1 was not paralleled with an upregulation of its mRNA, or with a significant stabilization of the protein. Moreover, PTOV1 was required for the activation of c-Jun in response to IGF-1, a promoter of cell motility and invasion. 30 Our observations, together with other evidences, suggest that, in prostate cancer, PTOV1 and RACK1 potentiate the activity of c-Jun though different mechanisms, PTOV1 by increasing the rate of c-Jun translation, and RACK1 by protecting c-Jun from proteasome degradation mediated by a FBW7-bearing SCF ubiquitin ligase. 53 Of note, after treatment with IGF-1 or phorbol ester, PTOV1, RACK1 and rpS6 rapidly colocalized at membrane ruffles (Figures 1d and 2e) , suggesting that growth factor stimulation co-opts the protein synthesis machinery to membrane structures, presumably to facilitate the local synthesis of proteins involved in movement and invasion. 18 Our results suggest that PTOV1 participates in these events, possibly by promoting the translation of specific subsets of mRNAs involved in those processes, such as c-Jun and urokinase receptor. AP1 complexes are also known to promote the transcription of proteases that enhance invasiveness, 31, 33 even with limited downregulation of cell-cell adhesion molecules such as E-cadherin and b-catenin. 40 This is pertinent to our observation of enhanced invasiveness of prostate epithelial cells induced by PTOV1 or c-Jun without significant effects on E-cadherin or b-catenin levels. Our findings that PTOV1 is required for optimal tumorigenesis and metastatic spread of PC-3 prostate cancer cells also highlights the importance of this protein in the expression of aggressive neoplastic phenotypes. In further support of the relevance to prostate cancer, we found that the expression levels of PTOV1 and c-Jun, both total and phosphorylated protein, display a significant and correlated increase from non-metastatic to metastatic primary prostate adenocarcinomas and to lymph node metastases. Similarly, results in human tumors, including prostate cancer, have shown a correlation between elevated JNK activity and poor clinical outcome. 54, 55 Collectively, our observations suggest that, in the course of malignant progression, prostate tumors express abnormally high levels of PTOV1 to upregulate c-Jun translation and activity as a mechanism to enable and promote a full-blown metastatic phenotype.
MATERIALS AND METHODS
Cell culture, reagents and antibodies PC-3, MDCK and COS-7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). PC-3 cells were cultured in RPMI-1640 medium (Gibco Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 1% glutamine and antibiotics. COS-7 and MDCK cells were maintained in modified Eagle's medium containing 10% fetal bovine serum and supplemented as above. Cells were grown at 37 1C in an atmosphere of 5% CO 2 -95% air and 99% humidity. Rapamycin and PP242 were from Sigma-Aldrich (Alcobendas, Madrid, Spain). Antibodies were from the following sources: mouse anti-RACK1, BD Transduction Laboratories (Lexington, KY, USA); rabbit antiphosphorylated c-Jun (Ser 73), Abcam (Cambridge, UK); rabbit anti-ERK1/2, Upstate (Billerica, MA, USA); rabbit anti-phosphorylated 4E-BP1 (Thr37/46) and anti-rpS6, Cell Signaling (Danvers, MA, USA); rat anti-HA, Roche Diagnostics (Mannheim, Germany); mouse anti-GST (1E5), rabbit anti-c-Jun (H-79), goat anti-actin (I-19), Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Transfections and transduction of cells
Transfections were done with TransIT-Prostate transfection kit (Mirus Bio Corp., Madison, WI, USA) for PC-3 cells, and with Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) for COS-7 cells. Lentiviral particles were produced in HEK293T by co-transfection of plasmids carrying shRNA or HA-PTOV1 templates and plasmids encoding gag, pol and env proteins. After 48 h, viral particles were harvested, concentrated by ultracentrifugation and transduced into cells in the presence of polybrene (10 mg/ml). Transduced cells were selected with 0.5 mg/ml puromycin (Sigma-Aldrich) for 3 days. Cells transduced with p-HA-PTOV1-IRES-EGFP were selected by flow cytometry.
Plasmids
Full-length human PTOV1 cDNA was subcloned into EcoRI and XhoI sites of pCMV-HA (Clontech Laboratories, Mountainview, CA, USA) to generate pHA-PTOV1, and into EcoRI and NotI sites of pGEX-4T-2 (GE Healthcare, Little Chalfont, UK) to generate pGST-PTOV1. The lentiviral p-HA-PTOV1-IRES-GFP plasmid was generated by replacing the Luciferase cDNA from pRRL-Luc-IRES-EGFP (a gift from Dr Luis Á lvarez-Vallina, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain) with HA-tagged human PTOV1. The PTOV1-A domain (residues 14-188) and B domain (residues 184 to carboxy terminus) were amplified by PCR and cloned into BamHI and SalI sites of pGEX-6P-1 to obtain pGST-A domain and pGST-B domain. GST-RACK1 was a kind gift from G. Bolger (University of Utah, Salt Lake City, Utah, USA), Jun-HA from D. Bohmann (University of Rochester Medical Center, Rochester, NY, USA), the c-Jun dominant negative Tam67 variant 34 
Pull-down assays
Purified GST-fusion proteins (25 mg) were incubated with 50 ml of glutathione-Sepharose beads for 4 h. Cells were lysed in 300 ml of lysis buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 1% Triton X-100, 5 mM NaF, 2 mM Na 3 VO 4 and protease inhibitors), centrifuged and supernatants incubated overnight with the previous complex. Beads were washed in lysis buffer and bound proteins recovered by boiling in Laemmli buffer.
Real-time PCR
Total RNA was extracted with the RNeasy mini kit (Qiagen, Valencia, CA, USA), reverse transcribed and real-time PCR performed with the Universal Probe Library (Roche Diagnostics) on a LightCycler 480 RealTime PCR instrument (Roche Diagnostics). Primers are shown in Supplementary  Table 1 . The DDCt method was applied to estimate relative transcript levels. rpS18 amplification levels were used as internal references. Determinations were done in triplicate and values presented as mean ± s.e.m.
Polysomal profiling and fraction analysis PC-3 cell lysates (15 mM Tris/HCl pH 7.5, 300 mM NaCl, 15 mM MgCl 2 , 1% Triton X-100, 150 mg/ml cycloheximide, 40 units/ml RNAsin and complete EDTA-free protease inhibitors) were clarified by centrifugation and layered on 15-50% sucrose gradients. For EDTA treatment, after centrifugation cell lysates were incubated with 25 mM EDTA for 30 min at 4 1C, before loading sucrose gradients. After centrifugation at 37 000 r.p.m. at 4 1C for 2.5 h, fractions were precipitated with trichloroacetic acid, separated by SDSpolyacrylamide gel electrophoresis and analyzed by western blotting. For RNA analysis, RNA was extracted from each fraction with phenol/ chloroform/isoamyl alcohol (25:24:1) and analyzed on a 1% agarose gel.
Bulk protein synthesis COS-7 cells were incubated for 2 h with methionine-free Dulbecco's modified Eagle's medium at 37 1C and pulse labeled (30 min) with 75 mCi/ ml [ 
Western blotting
Western blotting analyses were performed as described. 8 Specific reactivity to antibodies was detected with a chemiluminescent substrate (GE Healthcare). Actin signal was used to monitor protein loading and transfer.
RNA interference
shRNA sequence 1439 (Sigma-Aldrich) and a small interfering RNA duplex (Dharmacon, Lafayette, CO, USA) were used for PTOV1 knockdown. Target sequences are shown in Supplementary Table 3. Immunoprecipitation Immunoprecipitations were performed as described. 8 Immunoprecipitated complexes were analyzed by SDS-polyacrylamide gel electrophoresis and western blotting. Control immunoprecipitation experiments were performed with isotype-matched unrelated antibodies.
Immunofluorescence
Immunofluorescence was performed with cells cultured on coverslips as described. 8 Images were captured in an inverted fluorescence confocal microscope (FV1000, Olympus, Tokyo, Japan).
Chromatin immunoprecipitation
Chromatin was immunoprecipitated using the Magna ChIP Chromatin Immuno Precipitation kit (Millipore, Billerica, MA, USA), the precipitated DNA purified and used as a template for PCR reactions. Primers used for PCR in chromatin immunoprecipitation experiments are described in Supplementary Table 2 .
Wound-healing assay Cells were grown to confluence and proliferation blocked with 50 nM mitomycin C (Sigma-Aldrich) for 2 h. Monolayers were scratched with a pipette tip and phase-contrast images of selected fields were acquired at 0, 18 and 24 h with an inverted microscope (BX61, Olympus).
In vitro invasion assays
Assays were performed as described 56 using growth factor-reduced Matrigel-coated 8-mm pore size Transwell chambers (BD Bioscience, Franklin Lakes, NJ, USA). Invasive cells at the bottom chamber were stained with Hoechst 33258 and counted. Each condition was tested in triplicate.
In vivo tumorigenic assays PC-3/shControl and PC-3/shPTOV1 cells (3 Â 10 6 ) in 100 ml of PBS were inoculated subcutaneously in the right flank of 6-week-old male SCIDbeige mice (n ¼ 5 for each cell line; Charles River Laboratories, Barcelona, Spain). All animal experimental procedures were approved by the Vall d'Hebron Hospital Animal Experimentation Ethics Committee. Tumor growth was monitored twice a week by calliper measurements (D Â d 2 /2, where D is the major diameter and d the minor diameter). After reaching 1.5 cm in diameter, tumors were excised, weighted and tumor/control (T/C) weight ratio calculated by dividing the median value of the tumor weight of the test tumors with respect to the control group. Mice were monitored for metastatic growth after tumor excision to detect secondary metastases by in vivo bioluminescent imaging of the animals using the IVIS Spectrum Imaging System equipped with the Living Image 4.0 software (Caliper Life Sciences, Hopkinton, MA, USA). Experimental end point was metastasis detection after which mice were euthanized.
Immunohistochemistry
Samples procured from radical prostatectomies were processed, diagnosed and stored in the Department of Pathology of the Vall d'Hebron University Hospital and Hospital Clínic. A total of 36 primary prostate adenocarcinoma samples were selected, 10 with low Gleason (o 7), 10 with high Gleason (X 7) scores and 16 metastatic adenocarcinomas with matched metastastatic lymph nodes. Informed consent was obtained for all samples, following the Spanish Biomedical Research Law and procedures approved by the ethics committees of the two institutions. Antigen retrieval and slide staining were performed as described. 3 Isotypematched control antibodies gave negative stainings in all cases.
Immunostaining was evaluated by a semiquantitative Histo Score (Hscore) method that considers the percentage of positive cells and their staining intensity [Hscore ¼ 1 Â (% weak) þ 2 Â (% moderate) þ 3 Â (% intense) in a range between 0 and 300]. Cases with fewer than 10% of positive cells were considered negative.
Statistics
Results are expressed as means ± standard errors of the means. The Student's t-test was used for statistical analysis and the Pearson coefficient to analyze distributions of qualitative variables. A P-value o0.05 was taken as the level of significance. These analyses were performed using Excel package.
